SCHEMBL3132152

SCHEMBL3132152

CCOc1cc(Nc2ccc(C(=O)O)cc2)ccc1OC(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
KMT2A Q03164 4/20 0.53
MAPT P10636 3/20 0.53
MEN1 O00255 3/20 0.53
MAPK1 P28482 1/20 0.53
POLB P06746 3/20 0.47
THRB P10828 1/20 0.47
TSHR P16473 1/20 0.47
RAB9A P51151 4/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
HTT P42858 2/20 0.45
KDM4E B2RXH2 1/20 0.45
GLA P06280 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
AGPAT2 O15120 1/20 0.44
CASP6 P55212 1/20 0.44
PDE4A P27815 2/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3123192 0.88 PDE4A (0.48) LMNAKMT2AMAPTMEN1MAPK1
SCHEMBL3129788 0.86 HTT (0.51) LMNAKMT2AMAPTMEN1MAPK1
SCHEMBL7371299 0.85 TSHR (0.63) LMNAKMT2AMAPTMEN1MAPK1
SCHEMBL3215132 0.85 KMT2A (0.49) LMNAKMT2AMAPTMEN1MAPK1
SCHEMBL28033776 0.78 KMT2A (0.56) LMNAKMT2AMAPTMEN1MAPK1
SCHEMBL3126642 0.76 AKR1C3 (0.55) KMT2AMAPTMEN1MAPK1POLB
SCHEMBL16951532 0.74 RAB9A (0.52) LMNAKMT2AMAPTMEN1MAPK1
SCHEMBL3205372 0.73 ABCG2 (0.42) LMNAKMT2AMAPTMEN1MAPK1
SCHEMBL7089045 0.73 TSHR (0.65) LMNAKMT2AMAPTMEN1MAPK1
SCHEMBL15521539 0.72 PDE4D (0.51) LMNAMAPK1TSHRRAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B LMNA 3769/4885KMT2A 1324/4885MAPT 4197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.